Meinian Onehealth(SZ:002044) China Post Securities·2025-04-21 07:06Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase in stock price of over 20% compared to the benchmark index within the next six months [8][15]. Core Insights - The company reported a revenue of 10.702 billion yuan in 2024, a decrease of 1.76% year-on-year, with a net profit attributable to shareholders of 282 million yuan, down 44.18% [3][8]. - The average revenue per customer (ARPU) increased by 8% to 672 yuan, while the total number of customers decreased by 12% to 15.38 million [4][6]. - The company is expanding its AI strategy, with AI-related revenue contributing 216 million yuan, representing 24% of total income from individual tests [6][8]. - The company plans to acquire equity in 19 health examination centers to enhance market share and optimize its business structure [7][8]. Financial Summary - The company’s gross margin for 2024 was 42.78%, remaining stable, while the net profit margin decreased to 2.64% due to credit impairment losses [5][8]. - Forecasted revenues for 2025, 2026, and 2027 are 11.717 billion yuan, 12.698 billion yuan, and 13.726 billion yuan, respectively, with corresponding net profits of 602 million yuan, 901 million yuan, and 1.152 billion yuan [8][11]. - The projected price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are 34, 23, and 18, respectively [8][11].